# EDGAR Filing Document

**Accession Number:** 0001404644
**File Stem:** 0001404644-26-000022
**Filing Date:** 2026-3
**Character Count:** 33379
**Document Hash:** deca3b4d7407ca99ffd9df4700099cc9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001404644-26-000022.hdr.sgml**: 20260324

**ACCESSION NUMBER**: 0001404644-26-000022

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260324

**DATE AS OF CHANGE**: 20260324

**EFFECTIVENESS DATE**: 20260324

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Neurogene Inc.
- **CENTRAL INDEX KEY:** 0001404644
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 980542593
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-294567
- **FILM NUMBER:** 26786425

**BUSINESS ADDRESS:**
- **STREET 1:** 535 W 24TH STREET
- **STREET 2:** 5TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10011
- **BUSINESS PHONE:** (877) 237-5020

**MAIL ADDRESS:**
- **STREET 1:** 535 W 24TH STREET
- **STREET 2:** 5TH FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10011

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Neoleukin Therapeutics, Inc.
- **DATE OF NAME CHANGE:** 20190812

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AQUINOX PHARMACEUTICALS, INC
- **DATE OF NAME CHANGE:** 20140128

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AQUINOX PHARMACEUTICALS (USA) INC
- **DATE OF NAME CHANGE:** 20070626

**As filed with the Securities and Exchange Commission on March 24, 2026**

**Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549** 

**FORM S-8**

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

**Neurogene Inc.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **98-0542593** |
| (State or Other Jurisdiction of Incorporation or<br>Organization) | (I.R.S. Employer Identification No.) |

---

**535 W 24th Street, 5th Floor**

**New York, NY 10011**

(Address of Principal Executive Offices, Zip Code)

**Neurogene Inc. 2023 Equity Incentive Plan** 

**Neurogene Inc. 2023 Employee Stock Purchase Plan**

(Full title of the plan)

**Donna M. Cochener**

**Senior Vice President, General Counsel**

**Neurogene Inc.**

**535 W 24th Street, 5th Floor**

**New York, NY 10011**

**(877) 237-5020**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Ryan A. Murr, Esq.

Branden C. Berns, Esq.

Gibson, Dunn & Crutcher LLP

One Embarcadero Center, Suite 2600

San Francisco, CA 94111

Telephone: (415) 393-8200

Facsimile: (415) 393-8306

______________________________________________

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | □ | Accelerated filer | □ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| | | Emerging growth company | □ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. □

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 (this "***Registration Statement***") is being filed by Neurogene Inc. (the "***Registrant***") to register (i) 891,294 shares of the Registrant's common stock, par value $0.000001 per share ("***Common Stock***") issuable pursuant to the Neurogene Inc. 2023 Equity Incentive Plan (the "***2023 Plan***") that became issuable under the 2023 Plan as a result of an automatic annual increase on January 1, 2026, and (ii) 222,823 shares of Common Stock issuable pursuant to the Neurogene Inc. 2023 Employee Stock Purchase Plan (the "***2023 ESPP***") that became issuable under the 2023 ESPP as a result of an automatic annual increase on January 1, 2026.

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

**Item 1.&nbsp;&nbsp;&nbsp;&nbsp;Plan Information** 

The documents containing the information specified in Part I of this Registration Statement will be delivered to employees as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the "***Securities Act***"). In accordance with the instructions to Part I of Form S-8, such documents are not being filed with the Securities and Exchange Commission (the "***SEC***") either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. Such documents and the documents incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3.&nbsp;&nbsp;&nbsp;&nbsp;Incorporation of Certain Documents by Reference**

The following documents, which have previously been filed by the Registrant with the SEC pursuant to the Securities Act and pursuant to the Securities Exchange Act of 1934, as amended (the "***Exchange Act***"), are incorporated by reference herein and shall be deemed to be a part hereof:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&nbsp;&nbsp;&nbsp;the Registrant's Annual Report on <u>[Form 10-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001404644/000140464426000019/ngne-20251231.htm)</u> for the fiscal year ended December 31, 2025 filed with the SEC on March 24, 2026; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&nbsp;&nbsp;&nbsp;the description of the Common Stock contained in <u>[Exhibit 4.3](https://www.sec.gov/Archives/edgar/data/1404644/000140464424000020/ngne-2023form10xkxex43desc.htm)</u> to the Registrant's Annual Report on Form 10-K filed with the SEC on March 18, 2024, including all amendments or reports filed for the purpose of updating such description.

In addition, all documents subsequently filed by the Registrant with the SEC pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment to this Registration Statement which indicate that all securities offered hereby have been sold or which deregisters all securities remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents. Notwithstanding the foregoing, unless specifically stated to the contrary, none of the information that the Registrant discloses under Items 2.02 or 7.01 of any Current Report on Form 8-K that it may from time to time furnish to the SEC will be incorporated by reference into, or otherwise included in, this Registration Statement.

Any statement, including financial statements, contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or therein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

------

**Item 4.&nbsp;&nbsp;&nbsp;&nbsp;Description of Securities.**

Not applicable.

**Item 5.&nbsp;&nbsp;&nbsp;&nbsp;Interests of Named Experts and Counsel.** 

Not applicable.

**Item 6.&nbsp;&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.**

Section 145(a) of the Delaware General Corporation Law (the "***DGCL***") provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, other than an action by or in the right of the corporation, by reason of the fact that such person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with such action, suit or proceeding if the person acted in good faith and in a manner the person reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful.

Section 145(b) of the DGCL provides that a Delaware corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that such person acted in any of the capacities set forth above, against expenses (including attorneys' fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if the person acted in good faith and in a manner the person reasonably believed to be in, or not opposed to, the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation, unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought shall determine, upon application, that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the court shall deem proper.

Further subsections of DGCL Section 145 provide that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)to the extent a present or former director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections (i) and (ii) of Section 145 or in the defense of any claim, issue or matter therein, such person shall be indemnified against expenses, including attorneys' fees, actually and reasonably incurred by such person in connection therewith;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)the indemnification and advancement of expenses provided for pursuant to Section 145 shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under any bylaw, agreement, vote of stockholders or disinterested directors or otherwise; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)the corporation shall have the power to purchase and maintain insurance of behalf of any person who is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person's status as such, whether or not the corporation would have the power to indemnify such person against such liability under Section 145.

------

As used in this Item 6, the term "proceeding" means any threatened, pending, or completed action, suit, or proceeding, whether or not by or in the right of Registrant, and whether civil, criminal, administrative, investigative or otherwise.

Section 145 of the DGCL makes provision for the indemnification of officers and directors in terms sufficiently broad to indemnify officers and directors of the Registrant under certain circumstances from liabilities (including reimbursement for expenses incurred) arising under the Securities Act. The Registrant's organizational documents provide, in effect, that, to the fullest extent and under the circumstances permitted by Section 145 of the DGCL, the Registrant will indemnify any and all of its officers and directors. The Registrant has entered into indemnification agreements with its officers and directors. The Registrant may, in its discretion, similarly indemnify its employees and agents. The Registrant's Certificate of Incorporation also relieves the Registrant's directors from monetary damages to the Registrant or its stockholders for breach of such director's fiduciary duty as a director to the fullest extent permitted by the DGCL. Under Section 102(b)(7) of the DGCL, a corporation may relieve its directors from personal liability to such corporation or its stockholders for monetary damages for any breach of their fiduciary duty as directors except (i) for a breach of the duty of loyalty, (ii) for failure to act in good faith, (iii) for intentional misconduct or knowing violation of law, (iv) for willful or negligent violations of certain provisions in the DGCL imposing certain requirements with respect to stock repurchases, redemptions and dividends or (v) for any transactions from which the director derived an improper personal benefit.

The Registrant has purchased and expects to maintain insurance policies that, within the limits and subject to the terms and conditions thereof, cover certain expenses and liabilities that may be incurred by directors and officers in connection with proceedings that may be brought against them as a result of an act or omission committed or suffered while acting as a director or officer of the Registrant.

**Item 7.&nbsp;&nbsp;&nbsp;&nbsp;Exemption from Registration Claimed.**

Not applicable.

**Item 8.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits.** 

---

| | |
|:---|:---|
| **Exhibit <br>No.** | **Exhibit Description** |
| 4.1 | <u>[Amended and Restated Certificate of Incorporation of Neurogene Inc. (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K filed with the SEC on December 19, 2023)](https://www.sec.gov/Archives/edgar/data/1404644/000119312523298152/d648703dex32.htm)</u>. |
| 4.2 | <u>[Amended and Restated Bylaws of Neurogene Inc. (incorporated by reference to Exhibit 3.3 to the Registrant's Current Report on Form 8-K filed with the SEC on December 19, 2023)](https://www.sec.gov/Archives/edgar/data/1404644/000119312523298152/d648703dex33.htm)</u>. |
| 4.3 | <u>[Specimen Common Stock Certificate of Neurogene Inc. (incorporated by reference to Exhibit 4.1 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 filed with the SEC on May 13, 2014)](https://www.sec.gov/Archives/edgar/data/1404644/000119312514195836/d704250dex41.htm)</u>. |
| 5.1\* | <u>[Opinion of Gibson, Dunn & Crutcher LLP.](neurogene-evergreenformsx8.htm)</u> |
| 23.1\* | <u>[Consent of Deloitte & Touche LLP, Independent Registered Public Accounting Firm.](exhibit231-deloitteconsent.htm)</u> |
| 23.2\* | <u>[Consent of Gibson, Dunn and Crutcher (contained in Exhibit 5.1).](neurogene-evergreenformsx8.htm)</u> |
| 24.1\* | <u>[Power of Attorney (included on the signature page to this Registration Statement).](#iab3ccaacdb6b42d4864dd441acc96743_37)</u> |
| 99.1 | <u>[Neurogene Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/ngne2023equityincentivepla.htm)[1](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/ngne2023equityincentivepla.htm)[0.](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/ngne2023equityincentivepla.htm)[1 to Registrant](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/ngne2023equityincentivepla.htm)['](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/ngne2023equityincentivepla.htm)[s Current Report on Form 8-K filed with the Sec](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/ngne2023equityincentivepla.htm)[urities and Exchange Commission on June 12, 2025)](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/ngne2023equityincentivepla.htm)</u>. |
| 99.2 | <u>[Neurogene Inc. 2023 Employee Stock Purchase Plan (incorporated by reference to Exhibit](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/a2023esppasamendedjune2025.htm)[1](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/a2023esppasamendedjune2025.htm)[0.2 t](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/a2023esppasamendedjune2025.htm)[o Registrant](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/a2023esppasamendedjune2025.htm)['](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/a2023esppasamendedjune2025.htm)[s Current R](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/a2023esppasamendedjune2025.htm)[eport on Form 8-K filed with the](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/a2023esppasamendedjune2025.htm)[Securities and E](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/a2023esppasamendedjune2025.htm)[xcha](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/a2023esppasamendedjune2025.htm)[nge Commission](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/a2023esppasamendedjune2025.htm)[on June 12, 2025).](https://www.sec.gov/Archives/edgar/data/1404644/000140464425000053/a2023esppasamendedjune2025.htm)</u> |
| 107.1\* | <u>[Filing Fee Table.](exfilingfees.htm)</u> |

---

______________

\* &nbsp;&nbsp;&nbsp;&nbsp;Filed herewith

------

**Item 9.&nbsp;&nbsp;&nbsp;&nbsp;Undertakings.**

(a) The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Filing Fee Tables" or "Calculation of Registration Fee" table, as applicable, in the effective registration statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

*provided, however*, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on March 24, 2025.

---

| | |
|:---|:---|
| **NEUROGENE INC.** | **NEUROGENE INC.** |
| By: | /s/ Rachel McMinn, Ph.D. |
| Name: | Rachel McMinn, Ph.D. |
| Title: | Chief Executive Officer |

---

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints each of Rachel McMinn, Ph.D. and Christine Mikail, J.D., and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the SEC, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities indicated on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Rachel McMinn, Ph.D. | Chief Executive Officer and Chair of the Board<br>(*Principal Executive Officer*) | March 24, 2026 |
| Rachel McMinn, Ph.D. | Chief Executive Officer and Chair of the Board<br>(*Principal Executive Officer*) | March 24, 2026 |
| /s/ Christine Mikail, J.D. | Chief Financial Officer and President <br>(*Principal Financial and Accounting Officer*) | March 24, 2026 |
| Christine Mikail, J.D. | Chief Financial Officer and President <br>(*Principal Financial and Accounting Officer*) | March 24, 2026 |
| /s/ Robert Baffi, Ph.D. | Director | March 24, 2026 |
| Robert Baffi, Ph.D. | Director | March 24, 2026 |
| /s/ Cory Freedland, Ph.D. | Director | March 24, 2026 |
| Cory Freedland, Ph.D. | Director | March 24, 2026 |
| /s/ Sarah B. Noonberg, M.D., Ph.D. | Director | March 24, 2026 |
| Sarah B. Noonberg, M.D., Ph.D. | Director | March 24, 2026 |
| /s/ Rohan Palekar | Director | March 24, 2026 |
| Rohan Palekar | Director | March 24, 2026 |
| /s/ Robert Keith Woods | Director | March 24, 2026 |
| Robert Keith Woods | Director | March 24, 2026 |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? exfilingfees

**Exhibit 107.1**

**Calculation of Filing Fee Tables**

**FORM S-8**

(Form Type)

**NEUROGENE INC.**

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u> 

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered (1)** | **Proposed Maximum<br>Offering Price Per Unit** | **Maximum<br>Aggregate<br>Offering Price** | **Fee Rate** | **Amount of<br>Registration Fee** |
| Equity(2) | Common Stock, to be issued under the Neurogene Inc. 2023 Equity Incentive Plan (the "2023 Plan") | Rule 457(a)  | 891294 | $18.825 | $16778609.55 | $138.10 per $1,000,000 | $2317.13 |
| Equity(3) | Common Stock, to be issued under the Neurogene Inc. 2023 Employee Stock Purchase Plan (the "ESPP") | Rule 457(a)  | 222823 | $16.001 | $3565390.82 | $138.10 per $1,000,000 | $492.38 |
| **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $20344000.37 |  | $2809.51 |
| **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  | &nbsp;&nbsp;$— |
| **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $2809.51 |

---

(1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement also covers shares issued pursuant to certain anti-dilution provisions as set forth in the 2023 Plan and the ESPP, including, without limitation, shares issued as a result of any stock split, stock dividend, recapitalization or any other similar transaction effected without the Registrant's receipt of consideration that results in an increase in the number of shares of the Registrant's outstanding Common Stock.

(2) The number of shares of Common Stock represents 891,294 additional shares of Common Stock reserved for issuance under the 2023 Plan as a result of the automatic annual increase on January 1, 2026. The fee calculation is estimated in accordance with Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee on the basis of $18.825 per share, which represents the average of the high and low prices of the Registrant's Common Stock as reported on The Nasdaq Global Select Market on March 19, 2026.

(3) The number of shares of Common Stock represents 222,823 additional shares of Common Stock reserved for issuance under the ESPP as a result of the automatic annual increase on January 1, 2026. The fee calculation is estimated in accordance with Rules 457(c) and (h) of the Securities Act solely for the purpose of calculating the registration fee on the basis of a 15% discount from $18.825 per share, which represents the average of the high and low prices of the Registrant's Common Stock as reported on The Nasdaq Global Select Market on March 19, 2026, such discount representing the discount offered under the ESPP.

## Exhibit 5.1

![image_1.jpg](image_1.jpg)<br>

March 24, 2026

Neurogene Inc.

535 W 24th Street, 5th Floor New York, New York 10011

Re: Neurogene Inc.

Registration Statement on Form S-8

Ladies and Gentlemen:

We have examined the Registration Statement on Form S-8 (the "***Registration Statement***") of Neurogene Inc., a Delaware corporation (the "***Company***"), filed with the Securities and Exchange Commission (the "***Commission***") pursuant to the Securities Act of 1933, as amended (the "***Securities Act***"), in connection with the offering by the Company of up to 1,114,117 shares (the "***Shares***") of the Company's common stock, par value $0.000001 per share (the "***Common Stock***"). 891,294 of the Shares subject to the Registration Statement are reserved for issuance under the Neurogene Inc. 2023 Equity Incentive Plan (the "***2023 Plan***"), and 222,823 of the Shares subject to the Registration Statement are reserved for issuance under the Neurogene Inc. 2023 Employee Stock Purchase Plan (the "***ESPP***" and, together with the 2023 Plan, the "***Plans***").

We have examined the Plans and the originals, or photostatic or certified copies, of such records of the Company and certificates of officers of the Company and of public officials and such other documents as we have deemed relevant and necessary as the basis for the opinions set forth below. We have also made such other investigations as we have deemed relevant and necessary or appropriate in connection with the opinion hereinafter set forth. In our examination, we have assumed the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to us as copies. We have also assumed that there are no agreements or understandings between or among the Company and any participants in the Plans that would expand, modify or otherwise affect the terms of the Plans or the respective rights or obligations of the participants thereunder. Finally, we have assumed the accuracy of all other information provided to us by the Company during the course of our investigations, on which we have relied in issuing the opinion expressed below.

Based upon the foregoing examination and in reliance thereon, and subject to the assumptions stated and in reliance on statements of fact contained in the documents that we have examined, we are of the opinion that the shares of Common Stock issuable under the Plans, when issued and sold in accordance with the terms of the Plans and against payment therefor, and when the Registration Statement has become effective under the Securities Act, will be validly issued, fully paid and non-assessable.

We render no opinion herein as to matters involving the laws of any jurisdiction other than the Delaware General Corporation Law (the "***DGCL***"). This opinion is limited to the effect of the current state of the law of the DGCL and the facts as they currently exist. We assume no obligation to revise or supplement this opinion in the event of future changes in such law or the interpretations thereof or such facts. We express no opinion regarding any state securities laws or regulations.

**Gibson, Dunn & Crutcher LLP**<br>2000 Avenue of the Stars Suite 1200N \| Los Angeles, CA 90067-4700 \| T: 310.552.8500 \| F: 310.551.8741 \| gibsondunn.com<br>

------

<br> March 24, 2026<br>Page 2

![image_1.jpg](image_1.jpg)<br>

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving this consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission.

Very truly yours,

/s/ Gibson Dunn & Crutcher LLP

## Exhibit 23.1

**Exhibit 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our report dated March 24, 2026, relating to the financial statements of Neurogene Inc., appearing in the Annual Report on Form 10-K of Neurogene Inc. for the year ended December 31, 2025.

/s/ Deloitte & Touche LLP

Morristown, New Jersey

March 24, 2026

<br>